HI
IRLA

Harbour Investments’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Harbour Investments’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$163 – 3992
2025
Q3 		$163 Hold
1
– – ﹤0.01% 3607
2025
Q2 		$165 Buy
+1
New +$229 ﹤0.01% 3486

Other funds holding IRLA

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
SCM
Superstring Capital Management New York $158M AUM 418.32% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harbour Investments's IRLA Position: Q4 2025 in Review

Harbour Investments sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2025, closing a stake of 1 share — an estimated $163 sold.

Harbour Investments first reported a position in IRLA in Q2 2025 and held it in 2 quarters. The position peaked at $165 in Q2 2025. 62 funds tracked by Wall St. Rank hold IRLA as of Q4 2025.

  • Harbour Investments reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
  • Harbour Investments sold 1 IRulya Therapeutics Inc. Common Stock share in Q4 2025, an estimated $163.
  • Harbour Investments first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2025 and held it in 2 quarters.
  • Harbour Investments's IRulya Therapeutics Inc. Common Stock position peaked at $165 in Q2 2025.
  • 62 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2025.

Based on Harbour Investments's 13F filing for Q4 2025, filed 9 Feb 2026.